. At the opposite end of the spectrum are genes that are expressed in one or a few cell types; examples are those encoding growth hormone, albumin, insulin, protamine, and elastase (12) (13) (14) (15) ; HNF-1, hepatic nuclear factor 1 (3); HNF-3, hepatic nuclear factor 3 (4); HNF-4, hepatic nuclear factor 4 (5); Fos and Jun are proto-oncoproteins that constitute the transcription factor Al1 (6); NF-l, nuclear factor 1 (7); CREB, cAMP response element binding protein (8); and ARF6, adipogenic response factor 6 (9). transgene is cell type-specific. Cells expressing the -2086 bp PEPCK/hGH transgene (illustrated in Fig. 3-5 figure) . Each of the five upstream deletion endpoints, followed by its expression ratio and level of expression, is indicated below each of the diagrams.
For example, '-207 (3/9, 5%)" means that 3 of 9 mice bearing a transgene terminating at -207 bp expressed the gene at a level estimated to be 5% of the native PEPCK (Fig. 2 and Fig. 4) Fig. 3A are shown. The numbers in parentheses are the expression ratios and levels of expression of the transgenes in kidney (18) (19) (20) 33) .
It is also possible that the ectopic, chronic expression of foreign growth hormone has a suppressive effect on PEPCK transcription, as was the case with transferrin/hGH transgenic mice (17). This is unlikely with the hGH reporter because expression of the native PEPCK gene was not suppressed in transgenic mice with high levels of serum hGH (19). In contrast, bGH does inhibit PEPCK expression (18). Although we cannot explain the differences between human and bovine growth hormones, it is clear that biologically inert reporters must be used to verify these results. We are currently doing this with hGX, a frameshift mutant of hGH that produces an inactive protein product (17). Unlike the PEPCK/growth hormone transgenes, all three of the rat/chicken transgenes appeared to be expressed at the same levels as the endogenous PEPCK gene in the the kidney (Fig. 4) and + 69 bp (see Fig. 3B ). However, Fig. 3B ), is present at substantial concentrations in adipocytes (1). Moreover, C/EBP appears during adipogenesis, suggesting that it is involved in the process of adipocyte differentiation (1). This suggests that C/EBP does not act alone but must interact with other factors, perhaps in the region of the distal fat element. Indeed, one of our goals is to learn whether the distal fat-specific element requires an interaction with the PEPCK promoter and whether heterologous promoters will support fat-specific expression.
CONCLUSIONS AND FUTURE DIRECTIONS
Our long-range goal is to understand the transcriptional regulation of the PEPCK gene and use this information to develop a model for how single genes are expressed in multiple tissues. We have reviewed only a small part of the journey toward this goal. We have described work from three groups showing that hepatocytes, proximal renal tubule epithehial cells, and adipocytes utilizedifferentdir-actingelements to drive the PEPCK gene. The task for the next few years will 
